Status:
UNKNOWN
Mitochondrial Health and Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients
Lead Sponsor:
Ottawa Hospital Research Institute
Collaborating Sponsors:
University of Ottawa
University of Helsinki
Conditions:
Acute Kidney Injury (AKI)
Eligibility:
All Genders
18+ years
Brief Summary
Renal replacement therapy is a life-saving treatment for patients who have sudden and severe kidney failure. However, some of these patients blood pressure who receive this treatment could become unst...
Detailed Description
BACKGROUND: Acute kidney injury (AKI) that requires renal replacement therapy (RRT) affects 2% of all hospitalized patients and 15% of those admitted to ICU. Non-recovery of kidney function and conse...
Eligibility Criteria
Inclusion
- \>/=18 years;
- Diagnosis of stage 3 AKI per Kidney Disease Improving Global Outcomes (KDIGO) AKI guidelines;
- Starting SLED as first RRT received during current hospitalization.
Exclusion
- Prior kidney transplant;
- Prior nephrectomy;
- Any RRT in the previous year;
- Baseline estimated glomerular filtration rate (eGFR) \<15ml/min/1.73m2.
Key Trial Info
Start Date :
December 6 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05264285
Start Date
December 6 2021
End Date
September 30 2024
Last Update
September 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ottawa Hospital
Ottawa, Ontario, Canada, K2G 2H1